# Safety, Tolerability and PK of Imeglimin in Japanese Volunteers

> **NCT02373150** · PHASE1 · COMPLETED · sponsor: **Poxel SA** · enrollment: 48 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Imeglimin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02373150
- **Lead sponsor:** Poxel SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2017-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02373150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02373150, "Safety, Tolerability and PK of Imeglimin in Japanese Volunteers". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02373150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*